Maryland Heights, MO, June 20, 2016 --(PR.com
)-- According to a new market research report published by iHealthcareAnalyst, Inc., Cancer Diagnostics Testing Market – Global Diagnostics Methods and Applications Analysis and Forecast 2013-2020, the global cancer diagnostics testing market was valued at USD 90,556.2Million in 2013 and is estimated to reach USD 153,556.3 Million in 2020, expanding at a CAGR of 7.2% from 2015 to 2020.
Visit the Cancer Diagnostics Testing Market – Global Diagnostics Methods and Applications Analysis and Forecast 2013-2020 report at http://www.ihealthcareanalyst.com/report/cancer-diagnostics-market/.
There are many different ways to diagnose cancer. Cancer diagnostic testing involves tests and procedures to confirm the presence of disease and identify the correct tumor type, location, extent and stage. The most common diagnostic tests includes biopsy tests (bone marrow, endoscopic, needle biopsy), endoscopy tests (bronchoscopy, colonoscopy, colposcopy, sigmoidoscopy, etc.), diagnostic imaging (CT, MRI, PET, mammography, ultrasound, etc.), and detection of cancer-specific tumor biomarkers. The cancer diagnostics testing market report estimates the market size (Revenue USD million - 2013 to 2020) for market segmentation based on testing methods and their applications (organ or cell-specific cancer types – blood, breast, colorectal, kidney, liver, lung, ovarian, pancreatic, and prostate cancer) and forecasts growth trends (CAGR% - 2015 to 2020). It also provides the detailed market landscape and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments (acquisitions and alliances).
The global cancer diagnostics testing market is segmented as:
1. Diagnostic Method
1.1.1. Bone Marrow Biopsy
1.1.2. Endoscopic Biopsy
1.1.3. Needle Biopsy
1.3. Diagnostic Imaging
1.3.1. Computed Tomography (CT) Scan
1.3.2. Magnetic Resonance Imaging (MRI) Scan
1.3.4. Positron Emission Tomography (PET) Scan
1.4. Tumor Biomarker
1.4.1. Alpha-Fetoprotein (AFP) Tests
1.4.2. Anaplastic Lymphoma Kinase (ALK) Tests
1.4.3. BRCA Tests
1.4.4. CA 125 Tests
1.4.5. CA 19-9 Tests
1.4.6. Carcinoembryonic Antigen (CEA) Tests
1.4.7. Circulating Tumor Cells (CTC) Tests
1.4.8. EGFR Mutation Tests
1.4.9. HER2 Tests
1.4.10. KRAS Mutation Tests
1.4.11. Prostate Specific Antigen Tests
2.1. Blood Cancer
2.2. Breast Cancer
2.3. Colorectal Cancer
2.4. Kidney Cancer
2.5. Liver Cancer
2.6. Lung Cancer
2.7. Ovarian Cancer
2.8. Pancreatic Cancer
2.9. Prostate Cancer
3. Geography (Region, Country)
3.1. North America (U.S., Canada)
3.2. Latin America (Brazil, Mexico, Rest of LA)
3.3. Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
3.4. Asia Pacific (Japan, China, India, Rest of APAC)
3.5. Rest of the World
4. Company Profiles
4.1. Abbott Laboratories, Inc.
4.2. Ambry Genetics
4.3. AstraZeneca plc
4.4. bioMeriux SA
4.5. Eli Lilly and Company
4.6. Genoptix, Inc.
4.7. GlaxoSmithKline plc
4.8. Hoffmann-La Roche Ltd.
4.9. Pfizer, Inc.
iHealthcareAnalyst, Inc. is a global health care market research and consulting company providing market analysis, and competitive intelligence services to global clients. The Company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.
iHealthcareAnalyst, Inc. provides industry participants and stakeholders with strategically analyzed, unbiased view of market dynamics and business opportunities within its coverage areas.
2109, Mckelvey Hill Drive,
Maryland Heights, MO 63043